Amd §§6807 & 6810, Ed L (as proposed in S.36-A and A.2145-A); add §280-d, Pub Health L
Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.
NEW YORK STATE ASSEMBLY MEMORANDUM IN SUPPORT OF LEGISLATION submitted in accordance with Assembly Rule III, Sec 1(f)
BILL NUMBER: A5285
SPONSOR: Reyes TITLE OF BILL:
An act to amend the education law and the public health law, in relation
to prescription labels for mifepristone and misoprostol
PURPOSE OR GENERAL IDEA OF BILL:
To clarify provisions of Chapter 7 of the Laws of 2025 relating to
prescription labels for mifepristone or misoprostol.
SUMMARY OF PROVISIONS:
Section one would amend paragraph b-1 of subdivision one of section 6807
of the education law to provide that a dispensing practitioner may print
the address of their practice, rather than their own name or their prac-
tice's name on the prescription label for mifepristone or misoprostol.
Section two would amend subdivision 1-a of section 6810 of the education
law to clarify that a prescription label for mifepristone or misoprostol
shall include the name or address of the health care practice instead of
the name of the prescriber when requested by a prescriber.
Section three would add a new section 280-d to the public health law to
require that health care prescriber inform a patient if such prescriber
has included or has requested to include the name or address of the
prescribing health care practice instead of their own name on a
prescription label for mifepristone or misoprostol.
Section four would provide the effective date.
JUSTIFICATION:
This bill would provide necessary clarification of Chapter 7 of the Laws
of 2025 to ensure its effective implementation.
PRIOR LEGISLATIVE HISTORY:
New Bill.
FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS:
To be Determined.
EFFECTIVE DATE:
This act would take effect on the same date and in the same manner as a
chapter of the laws of 2025 amending the education law 1 relating to the
labeling of mifepristone, misoprostol, and their generic alternatives,
as proposed in legislative bills numbers S.36-A and A.2145-A, takes
effect.
STATE OF NEW YORK
________________________________________________________________________
5285
2025-2026 Regular Sessions
IN ASSEMBLY
February 12, 2025
___________
Introduced by M. of A. REYES -- read once and referred to the Committee
on Higher Education
AN ACT to amend the education law and the public health law, in relation
to prescription labels for mifepristone and misoprostol
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the
2 education law, as added by a chapter of the laws of 2025 amending the
3 education law relating to the labeling of mifepristone, misoprostol, and
4 their generic alternatives, as proposed in legislative bills numbers S.
5 36-A and A. 2145-A, is amended to read as follows:
6 b-1. Notwithstanding paragraph b of this section, the prescription
7 label for mifepristone[,] or misoprostol[, and their generic alterna-
8 tives] may include the name or address of the dispensing health care
9 practice instead of the name of the dispenser.
10 § 2. Subdivision 1-a of section 6810 of the education law, as added by
11 a chapter of the laws of 2025 amending the education law relating to the
12 labeling of mifepristone, misoprostol, and their generic alternatives,
13 as proposed in legislative bills numbers S. 36-A and A. 2145-A, is
14 amended to read as follows:
15 1-a. Notwithstanding subdivision one of this section, at the
16 prescriber's request, the prescription label for mifepristone[,] or
17 misoprostol[, and their generic alternatives may] shall include the name
18 or address of the prescribing health care practice instead of the name
19 of the prescriber.
20 § 3. The public health law is amended by adding a new section 280-d to
21 read as follows:
22 § 280-d. Patient notification of prescription label change. A health
23 care prescriber shall inform the patient if such prescriber has included
24 or has requested to include the name or address of the prescribing
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD09082-01-5
A. 5285 2
1 health care practice instead of the name of such prescriber on the
2 prescription label when prescribing mifepristone or misoprostol.
3 § 4. This act shall take effect on the same date and in the same
4 manner as a chapter of the laws of 2025 amending the education law
5 relating to the labeling of mifepristone, misoprostol, and their generic
6 alternatives, as proposed in legislative bills numbers S. 36-A and A.
7 2145-A, takes effect.
